Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-527 · 1 trial · 14 indications
The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.
| Arm | Type | Description |
|---|---|---|
| CDX-527 | EXPERIMENTAL | Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance. Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase. |
| Name | Type | Description |
|---|---|---|
| CDX-527 | DRUG | CDX-527 is administered by infusion every 2 weeks |
Key Inclusion Criteria: 1. Recurrent, locally advanced or metastatic solid tumor cancer excluding the following: MSI-low colorectal cancer, glioblastoma multiforme, prostate cancer, pancreatic cancer, mucosal and ocular melanoma. 2. Receipt of all standard therapies for the tumor type 3. Measurable...
Top 20 of 90 competitors
CDX-527 is an investigational bispecific antibody developed by Celldex Therapeutics for advanced solid tumors, including non-small cell lung cancer. It is designed to engage both PD-L1 and CD27, linking an immune checkpoint target with a costimulatory receptor. It has been studied in a single Phase 1 trial that is now completed.
CDX-527 targets PD-L1 and CD27. PD-L1 is an immune checkpoint ligand, and CD27 is a costimulatory receptor on T cells. By binding both, the bispecific antibody is designed to block the PD-L1 checkpoint pathway while simultaneously delivering a costimulatory signal through CD27 to activate antitumor T cell responses.
CDX-527 is developed by Celldex Therapeutics, Inc., a clinical-stage biopharmaceutical company that trades on the Nasdaq under the ticker CLDX. Celldex designed the agent as a PD-L1 x CD27 bispecific antibody and sponsored its clinical evaluation in patients with advanced malignancies.
CDX-527 is in Phase 1 development and is investigational. It has not been approved by the FDA. Its only clinical trial, NCT04440943, has been completed, and no active trials of CDX-527 are currently listed. The study enrolled 27 patients with advanced solid tumors.
CDX-527 has been evaluated in one clinical trial, NCT04440943, titled A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies. The Phase 1 trial enrolled 27 adults across sites in the United States and is completed. It was an uncontrolled study without randomization or blinding.
CDX-527 was studied in non-small cell lung cancer as part of a Phase 1 trial in patients with advanced malignancies. That trial, NCT04440943, also enrolled patients with breast, gastric, renal, ovarian, bladder, esophageal, head and neck, and other solid tumors. The study is completed, and CDX-527 remains investigational.